Marina Frimer, MD, Talks Future Treatments in Uterine Cancer

Marina Frimer, MD, spoke about what the future holds for the treatment of patients with platinum-sensitive recurrent uterine cancer.

At The Society of Gynecologic Oncology (SGO) 2022 Annual Meeting on Women’s Cancer, CancerNetwork® spoke with Marina Frimer, MD, associate chief of Research & Academic Development Central Region, and associate professor at the Donald and Barbara Zucker School of Medicine at Hofsta/Nortwell Health in New Hyde Park, New York, about recruiting patients to a trial (NCT04080284) examining maintenance niraparib (Zejula) for platinum-sensitive recurrent uterine cancer.

Transcript:

For [patients with] uterine serous cancer, we have an option for trastuzumab [Herceptin] in women who have a HER2 mutation. However, in women who don’t [harbor a mutation we don’t] have any other maintenance therapy options available at this time. For those patients, we are able to discuss the trial participation.

We really want to open this trial so that other [clinicians can send patients who] may potentially fit the criteria. Given the rarity of the tumor type, it’s very difficult to recruit patients to this trial. We’re really hoping to increase our publicity at the meeting.

Reference

Frimer M, Nizam A, Sison C, et al. Phase II trial of maintenance niraparib in patients with stage III, stage IV or platinum-sensitive recurrent uterine serous carcinoma. Presented at: 2022 SGO Annual Meeting on Women’s Cancer; March 18-21, 2022. Phoenix, Arizona.